ࡱ> SUR bjbj .P 8Nbbbvvv8vt0$Vzbbb.bbfDBCGLD0tb8t : Please provide the following information relating to NSCLC patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive. If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below. Total number treated Stage IIIB/IV NSCLC PatientsIf unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided: Patients with NSCLC Stage IIIB/IV (Stage 3b/4)7 Total number NSCLC patients Other (please specify) Data not held/accessible Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months April 2018 to June 2018 inclusive, with the following therapies. Total number treated Stage IIIB/IV NSCLC PatientsIf unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided: Docetaxel (mono or combination therapy ) Total number NSCLC patients Other (please specify) Data not held/accessibleAtezolizumab (Tecentriq) Total number NSCLC patients Other (please specify) Data not held/accessibleNivolumab (Opdivo) Total number NSCLC patients Other (please specify) Data not held/accessiblePembrolizumab (Keytruda) Total number NSCLC patients Other (please specify) Data not held/accessible If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred: We only treat patients that are for best supportive care. Active treatment is provided by the Christie. Please see contact details below: The Christie NHS Foundation Trust Wilmslow Road Manchester M20 4BX United Kingdom FOI requests Information Governance Officer Tel: 0161 446 3000 Email:  HYPERLINK "mailto:FOI@christie.nhs.uk" FOI@christie.nhs.uk    ICD10 C33, C34  Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.  TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0; TNM staging for Stage IV NSCLC = Any T, any N, M1 Please include number for both those patients that present at stage III/IV and also those whose cancer has progressed to stage III/IV     :;LM\ r   @ A B C e f Y o   Z [ x y   H I f g ƵƮƵƮ hJ`h*CJOJQJ^JaJ-jhJ`h/\0JCJOJQJU^JaJ hJ`h/\ hJ`h/\CJOJQJ^JaJ#hJ`h/\5CJOJQJ^JaJ-jh:lh/\0JCJOJQJU^JaJ h:lh/\CJOJQJ^JaJ1\ ]   $$Ifa$gdJ`l $IfgdJ`l gd/\  B D d e H8888$Ifl kd$$IflF .#VFF  t06    44 lBapytJ`e f g h :""d$IfgdJ`l kd$$Ifl4\ .!#`FV`F  t06244 lBBap(ytJ`h -kd$$Ifl4J\ .!#BBF  t06244 lBap(ytJ`$Ifl  $Ifl d$IfgdJ`l  Y =88gd/\kd$$Ifl4Q\ .!#BBF  t06244 lBap(ytJ`Y Z  $$Ifa$gdJ`l $IfgdJ`l   8 9 Y Z H8888$Ifl kd$$IflF 7#VFF  t06    44 lBapytJ`Z [ \ ] :""d$IfgdJ`l kd$$Ifl4\ 7!#`FV`F  t06244 lBBap(ytJ`] w x y -kd$$Ifl4J\ 7!#BBF  t06244 lBap(ytJ`$Ifl y z { $Ifl d$IfgdJ`l  =%d$IfgdJ`l kd$$Ifl4Q\ 7!#BBF  t06244 lBap(ytJ` *kd$$Ifl4Q\ 7!#`FV`F  t06244 lBBap(ytJ`$Ifl  $Ifl d$IfgdJ`l  =%%d$IfgdJ`l kd $$Ifl4Q\ 7!#BBF  t06244 lBap(ytJ`    -kd $$Ifl4Q\ 7!#BBF  t06244 lBap(ytJ`$Ifl  & ' G H $Ifl d$IfgdJ`l H I J K :""d$IfgdJ`l kd $$Ifl4Q\ 7!#`FV`F  t06244 lBBap(ytJ`K e f g -kd $$Ifl4Q\ 7!#BBF  t06244 lBap(ytJ`$Ifl g h i $Ifl d$IfgdJ`l  =%d$IfgdJ`l kd $$Ifl4Q\ 7!#BBF  t06244 lBap(ytJ` *kd $$Ifl4Q\ 7!#`FV`F  t06244 lBBap(ytJ`$Ifl  $Ifl d$IfgdJ`l  =%%d$IfgdJ`l kd$$Ifl4Q\ 7!#BBF  t06244 lBap(ytJ` -(gd/\kd$$Ifl4Q\ 7!#BBF  t06244 lBap(ytJ`$Ifl p~vnkd$$Ifl#$ t0644 lap ytJ`$Ifl gd}=gd/\ p~~z~dRG@G@8h/\CJaJ hJ`h/\hJ`h/\CJaJ#h:lh}=5CJOJQJ^JaJ+jhYzCJOJQJU^JaJmH sH hYzjhYzU+h)Zh}=5CJOJQJ^JaJmH sH (h)Zh}=CJOJQJ^JaJmH sH h/\5CJOJQJ^JaJh}=5CJOJQJ^JaJ#h:lh*5CJOJQJ^JaJh:lCJOJQJ^JaJ h:lh*CJOJQJ^JaJ }}ss dgd/\gd/\gd/\gd/\nkdd$$Ifl#$ t0644 lap ytJ` jhYzUhYz h/\CJh/\CJaJh/\CJaJh/\jh/\0JUh:` dgd/\,1h. A!"#$% $$If!vh#v#v#v:V l  t065V55/ / / / BpytJ`$$If!vh#v#v#v #v:V l4 t06++5V55 5/ 2BBp(ytJ`$$If!vh#v#v#v #v:V l4J t06++,55 5/ 2Bp(ytJ`$$If!vh#v#v#v #v:V l4Q t06++,55 5/ 2Bp(ytJ`$$If!vh#v #v#vw:V l  t065V55/ / / / BpytJ`$$If!vh#v #v#v #v:V l4 t06++5V55 5/ 2BBp(ytJ`$$If!vh#v #v#v #v:V l4J t06++,55 5/ 2Bp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++,55 5/ 2Bp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++5V55 5/ 2BBp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++,55 5/ 2Bp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++,55 5/ 2Bp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++5V55 5/ 2BBp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++,55 5/ 2Bp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++,55 5/ 2Bp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++5V55 5/ 2BBp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++,55 5/ 2Bp(ytJ`$$If!vh#v #v#v #v:V l4Q t06++,55 5/ 2Bp(ytJ`$$If!vh#v$:V l t065$/  / p ytJ`$$If!vh#v$:V l t065$/ /  p ytJ`j 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nH sH tH J`J /\Normal dCJ_HaJmH sH tH DA D Default Paragraph FontRi@R 0 Table Normal4 l4a (k ( 0No List H@H /\0 Footnote Text dCJaJDoD /\0Footnote Text CharCJaJ@&`@ /\0Footnote ReferenceH*x`#x /\ Table Grid<:V0a dPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] :L@  P   $& e h Y  Z ] y  H K g   !"#%' XL# @0(  B S  ?$?G  ?OL}=/\:`Yz:l~J`*@ @UnknownG* Times New Roman5Symbol3. * Arial7.*{$ CalibriA$BCambria Math"1hi'i'1m%!0 JHX  $P/\2!xx English-Gallantry GerardGriffiths PamelaOh+'08 px    (0English-Gallantry GerardNormalGriffiths Pamela2Microsoft Office Word@F#@p9C@p9C1՜.+,D՜.+,, hp|  WWL  Title 8@ _PID_HLINKSApemailto:FOI@christie.nhs.uk  !"#$%&'(*+,-./012456789:;<=>?@ACDEFGHIKLMNOPQTRoot Entry FpUBCVData )1Table3WordDocument.PSummaryInformation(BDocumentSummaryInformation8JCompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q